Optimer receives production patent for CDI treatment

SAN DIEGO The U.S. Patent and Trademark Office has issued a production patent to Optimer Pharmaceuticals covering steps used in the manufacture of fidaxomicin, Optimer announced Monday.

The drug is in phase 3 testing as a treatment for Clostridium difficile infection, also known as CDI.

“The issuance of this production patent is another important milestone in strengthening the patent estate of our lead product candidate, fidaxomicin,” Optimer president and CEO Michael Chang stated. “We believe this patent and the issued polymorphic Form A patent, along with additional pending patent applications, will enhance our intellectual property protection for fidaxomicin.”

CDI causes inflammation of the colon, which often results in diarrhea but can also cause death in extreme cases.